Literature DB >> 29202467

Endothelial chimerism and vascular sequestration protect pancreatic islet grafts from antibody-mediated rejection.

Chien-Chia Chen1, Eric Pouliquen2, Alexis Broisat3, Francesco Andreata4, Maud Racapé5, Patrick Bruneval5, Laurence Kessler6,7, Mitra Ahmadi3, Sandrine Bacot3, Carole Saison-Delaplace1,2, Marina Marcaud2, Jean-Paul Duong Van Huyen5, Alexandre Loupy5,8, Jean Villard9, Sandrine Demuylder-Mischler10, Thierry Berney7,10, Emmanuel Morelon1,2,7,11, Meng-Kun Tsai12, Marie-Nathalie Kolopp-Sarda13, Alice Koenig1, Virginie Mathias14, Stéphanie Ducreux14, Catherine Ghezzi3, Valerie Dubois14, Antonino Nicoletti4, Thierry Defrance1, Olivier Thaunat1,2,7,11.   

Abstract

Humoral rejection is the most common cause of solid organ transplant failure. Here, we evaluated a cohort of 49 patients who were successfully grafted with allogenic islets and determined that the appearance of donor-specific anti-HLA antibodies (DSAs) did not accelerate the rate of islet graft attrition, suggesting resistance to humoral rejection. Murine DSAs bound to allogeneic targets expressed by islet cells and induced their destruction in vitro; however, passive transfer of the same DSAs did not affect islet graft survival in murine models. Live imaging revealed that DSAs were sequestrated in the circulation of the recipients and failed to reach the endocrine cells of grafted islets. We used murine heart transplantation models to confirm that endothelial cells were the only accessible targets for DSAs, which induced the development of typical microvascular lesions in allogeneic transplants. In contrast, the vasculature of DSA-exposed allogeneic islet grafts was devoid of lesions because sprouting of recipient capillaries reestablished blood flow in grafted islets. Thus, we conclude that endothelial chimerism combined with vascular sequestration of DSAs protects islet grafts from humoral rejection. The reduced immunoglobulin concentrations in the interstitial tissue, confirmed in patients, may have important implications for biotherapies such as vaccines and monoclonal antibodies.

Entities:  

Keywords:  Immunoglobulins; Immunology; Islet cells; Transplantation

Mesh:

Substances:

Year:  2017        PMID: 29202467      PMCID: PMC5749508          DOI: 10.1172/JCI93542

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  56 in total

1.  A technique of cervical heterotopic heart transplantation in mice.

Authors:  Z H Chen
Journal:  Transplantation       Date:  1991-12       Impact factor: 4.939

2.  Disappearance of T Cell-Mediated Rejection Despite Continued Antibody-Mediated Rejection in Late Kidney Transplant Recipients.

Authors:  Philip F Halloran; Jessica Chang; Konrad Famulski; Luis G Hidalgo; Israel D R Salazar; Maribel Merino Lopez; Arthur Matas; Michael Picton; Declan de Freitas; Jonathan Bromberg; Daniel Serón; Joana Sellarés; Gunilla Einecke; Jeff Reeve
Journal:  J Am Soc Nephrol       Date:  2014-11-06       Impact factor: 10.121

3.  Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry.

Authors:  Kellee M Miller; Nicole C Foster; Roy W Beck; Richard M Bergenstal; Stephanie N DuBose; Linda A DiMeglio; David M Maahs; William V Tamborlane
Journal:  Diabetes Care       Date:  2015-06       Impact factor: 19.112

4.  Alloreactivity against repeated HLA mismatches of sequential islet grafts transplanted in non-uremic type 1 diabetes patients.

Authors:  Corine A van Kampen; Pieter van de Linde; Gaby Duinkerken; Jolien J van Schip; Dave L Roelen; Bart Keymeulen; Daniel G Pipeleers; Frans H J Claas; Bart O Roep
Journal:  Transplantation       Date:  2005-07-15       Impact factor: 4.939

5.  Posttransplant donor-specific anti-HLA antibodies negatively impact pancreas transplantation outcome.

Authors:  D Cantarovich; S De Amicis; A Akl; A Devys; F Vistoli; G Karam; J-P Soulillou
Journal:  Am J Transplant       Date:  2011-09-11       Impact factor: 8.086

6.  Beta-score: an assessment of beta-cell function after islet transplantation.

Authors:  Edmond A Ryan; Breay W Paty; Peter A Senior; Jonathan R T Lakey; David Bigam; A M James Shapiro
Journal:  Diabetes Care       Date:  2005-02       Impact factor: 19.112

7.  Immunogenicity of Anti-HLA Antibodies in Pancreas and Islet Transplantation.

Authors:  Benjamin Chaigne; Kirsten Geneugelijk; Benoît Bédat; Mohamed Alibashe Ahmed; Gideon Hönger; Sophie De Seigneux; Sandrine Demuylder-Mischler; Thierry Berney; Eric Spierings; Sylvie Ferrari-Lacraz; Jean Villard
Journal:  Cell Transplant       Date:  2016-11       Impact factor: 4.064

8.  Complement-binding anti-HLA antibodies and kidney-allograft survival.

Authors:  Alexandre Loupy; Carmen Lefaucheur; Dewi Vernerey; Christof Prugger; Jean-Paul Duong van Huyen; Nuala Mooney; Caroline Suberbielle; Véronique Frémeaux-Bacchi; Arnaud Méjean; François Desgrandchamps; Dany Anglicheau; Dominique Nochy; Dominique Charron; Jean-Philippe Empana; Michel Delahousse; Christophe Legendre; Denis Glotz; Gary S Hill; Adriana Zeevi; Xavier Jouven
Journal:  N Engl J Med       Date:  2013-09-26       Impact factor: 91.245

9.  Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions.

Authors:  M Haas; B Sis; L C Racusen; K Solez; D Glotz; R B Colvin; M C R Castro; D S R David; E David-Neto; S M Bagnasco; L C Cendales; L D Cornell; A J Demetris; C B Drachenberg; C F Farver; A B Farris; I W Gibson; E Kraus; H Liapis; A Loupy; V Nickeleit; P Randhawa; E R Rodriguez; D Rush; R N Smith; C D Tan; W D Wallace; M Mengel
Journal:  Am J Transplant       Date:  2014-02       Impact factor: 8.086

10.  Access of protective antiviral antibody to neuronal tissues requires CD4 T-cell help.

Authors:  Norifumi Iijima; Akiko Iwasaki
Journal:  Nature       Date:  2016-05-18       Impact factor: 49.962

View more
  10 in total

Review 1.  Immunological Monitoring in Beta Cell Replacement: Towards a Pathophysiology-Guided Implementation of Biomarkers.

Authors:  Fanny Buron; Sophie Reffet; Lionel Badet; Emmanuel Morelon; Olivier Thaunat
Journal:  Curr Diab Rep       Date:  2021-04-25       Impact factor: 4.810

Review 2.  Advances in β-cell replacement therapy for the treatment of type 1 diabetes.

Authors:  Marie-Christine Vantyghem; Eelco J P de Koning; François Pattou; Michael R Rickels
Journal:  Lancet       Date:  2019-09-15       Impact factor: 79.321

3.  Missing Self-Induced Activation of NK Cells Combines with Non-Complement-Fixing Donor-Specific Antibodies to Accelerate Kidney Transplant Loss in Chronic Antibody-Mediated Rejection.

Authors:  Alice Koenig; Sarah Mezaache; Jasper Callemeyn; Thomas Barba; Virginie Mathias; Antoine Sicard; Béatrice Charreau; Maud Rabeyrin; Frédérique Dijoud; Cécile Picard; Vannary Meas-Yedid; Jean-Christophe Olivo-Marin; Emmanuel Morelon; Maarten Naesens; Valérie Dubois; Olivier Thaunat
Journal:  J Am Soc Nephrol       Date:  2020-11-25       Impact factor: 10.121

4.  Long-term Persistence of Allosensitization After Islet Allograft Failure.

Authors:  Paola Rios; David Baidal; Joana Lemos; Stephanie S Camhi; Marco Infante; Nathalia Padilla; Ana M Alvarez Gil; Virginia Fuenmayor; Jonathan Ambut; Fatima A Qasmi; Alejandro M Mantero; Shari Messinger Cayetano; Phillip Ruiz; Camillo Ricordi; Rodolfo Alejandro
Journal:  Transplantation       Date:  2021-11-01       Impact factor: 5.385

5.  Highly Variable Sialylation Status of Donor-Specific Antibodies Does Not Impact Humoral Rejection Outcomes.

Authors:  Thomas Barba; Jean Harb; Stéphanie Ducreux; Alice Koenig; Virginie Mathias; Maud Rabeyrin; Eric Pouliquen; Antoine Sicard; Dimitri Chartoire; Emilie Dugast; Thierry Defrance; Emmanuel Morelon; Sophie Brouard; Valérie Dubois; Olivier Thaunat
Journal:  Front Immunol       Date:  2019-03-20       Impact factor: 7.561

Review 6.  Chronic Kidney Disease-Associated Immune Dysfunctions: Impact of Protein-Bound Uremic Retention Solutes on Immune Cells.

Authors:  Maxime Espi; Laetitia Koppe; Denis Fouque; Olivier Thaunat
Journal:  Toxins (Basel)       Date:  2020-05-06       Impact factor: 4.546

Review 7.  Advanced in vitro Research Models to Study the Role of Endothelial Cells in Solid Organ Transplantation.

Authors:  Daphne M Peelen; Martin J Hoogduijn; Dennis A Hesselink; Carla C Baan
Journal:  Front Immunol       Date:  2021-02-10       Impact factor: 7.561

8.  The challenge of HLA donor specific antibodies in the management of pancreatic islet transplantation: an illustrative case-series.

Authors:  Mehdi Maanaoui; Mikael Chetboun; Isabelle Top; Vincent Elsermans; Julie Kerr-Conte; Kristell Le Mapihan; Frederique Defrance; Valéry Gmyr; Thomas Hubert; Myriam Labalette; Marc Hazzan; Marie-Christine Vantyghem; François Pattou
Journal:  Sci Rep       Date:  2022-07-21       Impact factor: 4.996

9.  Atypical hemolytic and uremic syndrome due to C3 mutation in pancreatic islet transplantation: a case report.

Authors:  Thibault Bahougne; Jérome Olagne; Marion Munch; Laura Braun-Parvez; Marie-Pierrette Chenard; Véronique Frémeaux-Bacchi; Sophie Caillard; Philippe Baltzinger; Michel Greget; Laurence Kessler; Bruno Moulin
Journal:  BMC Nephrol       Date:  2020-09-19       Impact factor: 2.388

10.  Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs.

Authors:  Jonathan Lopez; Marine Mommert; William Mouton; Andrés Pizzorno; Karen Brengel-Pesce; Mehdi Mezidi; Marine Villard; Bruno Lina; Jean-Christophe Richard; Jean-Baptiste Fassier; Valérie Cheynet; Blandine Padey; Victoria Duliere; Thomas Julien; Stéphane Paul; Paul Bastard; Alexandre Belot; Antonin Bal; Jean-Laurent Casanova; Manuel Rosa-Calatrava; Florence Morfin; Thierry Walzer; Sophie Trouillet-Assant
Journal:  J Exp Med       Date:  2021-08-06       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.